- Home
- DALN vs COEP Comparison
DALN vs COEP Comparison
Compare DALN & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- COEP
- Stock Information
- Founded
- DALN 1954
- COEP 2017
- Country
- DALN United States
- COEP United States
- Employees
- DALN N/A
- COEP N/A
- Industry
- DALN Newspapers/Magazines
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DALN Consumer Discretionary
- COEP Health Care
- Exchange
- DALN Nasdaq
- COEP Nasdaq
- Market Cap
- DALN 38.1M
- COEP 30.5M
- IPO Year
- DALN 2008
- COEP N/A
- Fundamental
- Price
- DALN $4.56
- COEP $9.37
- Analyst Decision
- DALN
- COEP
- Analyst Count
- DALN 0
- COEP 0
- Target Price
- DALN N/A
- COEP N/A
- AVG Volume (30 Days)
- DALN 50.1K
- COEP 43.6K
- Earning Date
- DALN 03-17-2025
- COEP 05-09-2025
- Dividend Yield
- DALN N/A
- COEP N/A
- EPS Growth
- DALN N/A
- COEP N/A
- EPS
- DALN 0.02
- COEP N/A
- Revenue
- DALN $125,391,000.00
- COEP N/A
- Revenue This Year
- DALN N/A
- COEP N/A
- Revenue Next Year
- DALN N/A
- COEP N/A
- P/E Ratio
- DALN $235.00
- COEP N/A
- Revenue Growth
- DALN N/A
- COEP N/A
- 52 Week Low
- DALN $2.98
- COEP $2.31
- 52 Week High
- DALN $7.86
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- DALN 27.68
- COEP 44.36
- Support Level
- DALN $5.20
- COEP $9.01
- Resistance Level
- DALN $6.31
- COEP $9.75
- Average True Range (ATR)
- DALN 0.49
- COEP 0.91
- MACD
- DALN -0.17
- COEP -0.07
- Stochastic Oscillator
- DALN 4.85
- COEP 42.98
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.